Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656315 | 1.00 | MEN1 (0.46) | MEN1KMT2ATSHRMAPK1PLA2G2A | |
| SCHEMBL20375621 | 1.00 | MEN1 (0.46) | MEN1KMT2ATSHRMAPK1PLA2G2A | |
| SCHEMBL14802705 | 0.91 | CYP3A4 (0.41) | TSHRPLA2G2ACYP3A4ALDH1A1BTN3A1 | |
| SCHEMBL19699812 | 0.91 | CYP3A4 (0.41) | TSHRPLA2G2ACYP3A4ALDH1A1BTN3A1 | |
| SCHEMBL4546795 | 0.87 | PLA2G2A (0.39) | TSHRPLA2G2ACYP3A4ALDH1A1BTN3A1 | |
| SCHEMBL12638785 | 0.87 | PLA2G2A (0.39) | TSHRPLA2G2ACYP3A4ALDH1A1BTN3A1 | |
| SCHEMBL20261782 | 0.87 | PLA2G2A (0.39) | TSHRPLA2G2ACYP3A4ALDH1A1BTN3A1 | |
| SCHEMBL20261774 | 0.87 | PLA2G2A (0.39) | TSHRPLA2G2ACYP3A4ALDH1A1BTN3A1 | |
| SCHEMBL8376491 | 0.87 | — | — | |
| Di(Hydroxyethyl)Ether SCHEMBL8829080 | 0.87 | TSHR (0.50) | MEN1KMT2ATSHRMAPK1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240026421-A1 | METHODS FOR CAPTURING LONG POLYNUCLEOTIDES FOR SEQUENCING SPECIFIC GENOMIC REGIONS | GENERATION BIOTECH, LLC (US) | 2024-01-25 | — | — | US | disclosed |
| US-11821023-B2 | Method for capturing long polynucleotides for sequencing specific gnomic regions | GENERATION BIOTECH, LLC (US) | 2023-11-21 | — | — | US | disclosed |
| US-11344633-B2 | Anti-nucleolin agent-conjugated nanoparticles | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC (US) | 2022-05-31 | — | — | US | disclosed |
| US-20180042849-A1 | COCHLEATES AND METHODS OF USING THE SAME TO ENHANCE TISSUE PENETRATION OF PHARMACOLOGICALLY ACTIVE AGENT | AQUARIUS BIOTECHNOLOGIES, INC. | 2018-02-15 | — | — | US | disclosed |
| US-20170095562-A1 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20150072351-A1 | HIGH-SENSITIVITY NUCLEIC ACID PREPARATION METHODS FOR THE DETECTION OF NUCLEIC ACID BY NUCLEIC ACID POLYMERASE | BIONEER CORPORATION (KR) | 2015-03-12 | — | — | US | disclosed |
| US-8835135-B2 | Reaction mixtures for prevention and alleviation of steric hindrance during single molecule synthesis | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (US) | 2014-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344633-B2 | Anti-nucleolin agent-conjugated nanoparticles | NCL, NOP56, NASP | MEN1 1294/4885KMT2A 2489/4885TSHR 2820/4885 |
| US-20180042849-A1 | COCHLEATES AND METHODS OF USING THE SAME TO ENHANCE TISSUE PENETRATION OF PHARMACOLOGICALLY ACTIVE AGENT | SLC10A1, SLC10A2, PCYT1A | MEN1 2378/4885KMT2A 4660/4885TSHR 3476/4885 |
| US-20170095562-A1 | ANTI-NUCLEOLIN AGENT-CONJUGATED NANOPARTICLES | NCL, NOP56, NASP | MEN1 1294/4885KMT2A 2489/4885TSHR 2820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.